Thrombin generation – Risk factor in melanoma patients and implant use
A research team in Jena, Germany, a runner-up to BMG LABTECH’s SPECTROstar Nano promotion, has proposed to use the SPECTROstar Nano to help study the role thrombin plays in thromboembolism in melanoma progression and in biomaterial implants.
As proposed, “plasma is obtained from melanoma patients and detection of the endogenous thrombin potential in plasma samples can be performed with small amounts of plasma in microplates using this feature of the SPECTROstar Nano spectrometer. A thrombin-specific colorimetric Thrombin Generation Assay (TGA, Haemoscan, Groningen, The Netherlands) is used to measure thrombin concentration. The TGA determines thrombin generation by concentration dependent reaction of a thrombin-specific chromogenic substrate. Incubation of plasma with thrombin substrate requires temperature control and can be performed in the SPECTROstar Nano system.”
For the biomaterial, it is proposed, “Thrombin generation can be measured at the SPECTROstar Nano spectrometer with the TGA. In cuvettes of the SPECTROstar Nano system thrombin generation can be measured in real time with different parameters, for instance speed of thrombin generation, time to peak and endogenous thrombin potential. Furthermore, also fibrin formation, which is converted by the serine protease thrombin from fibrinogen during coagulation, can be direct measured in real time at 405nm in SPECTROstar Nano cuvettes….Implant material is insoluble under physiological conditions. Cuvette use is one important advantage of the SPECTROstar Nano system, because insoluble biomaterial samples can be incubated with plasma probes without disturbing the course of beam. Therefore, biomaterial samples can be placed at the bottom of the cuvette, which is filled with blood plasma…Effects of biomaterial samples on thrombin generation and subsequent fibrin formation can be determined.”